Ultragenyx Pharmaceutical | RARE - Current Liabilities


Ultragenyx Pharmaceutical reported $351M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 361.44M 55.91M Jun/2026
Agios Pharmaceuticals USD 70.22M 11.37M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Immunic USD 38.36M 7.74M Mar/2026
Insmed USD 438.74M 77.74M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Kyowa Hakko Kirin JPY 182.39B 37.75B Jun/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Moderna USD 2.53B 139M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026